Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Publikováno v:
Endocr Relat Cancer
Immune checkpoint inhibitors have shown promising results in different cancers, and correlation between immune infiltration, expression of programmed death-ligand 1 (PD-L1) by tumor cells and response to immunotherapy has been reported. There is limi
Autor:
Guang Yang, Yanli Yao, Xing Liang, Chenghao Shao, Liang Tang, Meng Ji, Danlei Chen, Ligang Shi, Anan Liu, Junfeng Peng
Publikováno v:
Endocrine-Related Cancer. 28:X1-X2
Pancreatic neuroendocrine neoplasms (pNENs) are endocrine tumors arising in pancreas and is the most common neuroendocrine tumors. Mounting evidence indicates lncRNA H19 could be a determinant of tumor progression. However, the expression and mechani
Autor:
Günter Klöppel, Katja Steiger, Ayaka J. Iwata, Akira Sakurada, Naomi Oka, Hirotaka Ishida, Atsuko Kasajima, Hiroyoshi Suzuki, Hironobu Sasano, Wilko Weichert, Yoshinori Okada, Yuichi Ishikawa, Toru Kameya, Björn Konukiewitz
Publikováno v:
Endocrine-Related Cancer. 25:339-350
In the light of novel cancer immune therapies, the status of antitumor inflammatory response and its regulation has gained much attention in patients with lung cancer. Ample datasets exist for non-small-cell lung cancer, but those for pulmonary neuro
Autor:
Stephen Callahan, Mark Kidd, Daniele Alaimo, Irvin M. Modlin, Ignat Drozdov, Lisa Bodei, Nancy Teixiera
Publikováno v:
Endocrine-Related Cancer. 21:615-628
A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. We evaluated a PCR-based 51 transcript signature (NETest) and compared it to chromogranin A (CgA), pancreastatin (PST) and
Autor:
Brenda Gumz, Kimberly Kamp, Gregory Kaltsas, Richard A Feelders, Dik Kwekkeboom, Frederico Costa, Wouter de Herder
Publikováno v:
Endocrine-Related Cancer, 20(6), 825-831. Bioscientifica Ltd
Although 177Lu-octreotate is an effective treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), some patients will fail or develop disease progression necessitating further treatment. We examined whether the safety and
Autor:
Marianne Pavel, Katharina Detjen, Henning Jann, Tabea Neumann, Georg Hilfenhaus, Andreas Göhrig, Ulrich-Frank Pape, Dietmar Zdunek, Jean Marie Stassen, Georg Hess, Christian Fischer, Bertram Wiedenmann
Publikováno v:
Endocrine-Related Cancer. 20:305-319
Placental growth factor (PlGF), a VEGF-homolog implicated in tumor angiogenesis and adaptation to antiangiogenic therapy, is emerging as candidate target in malignancies. Here, we addressed the expression, function, and prognostic value of PlGF in ne
Autor:
Xihong Lin, Jennifer A. Chan, Laurie Buchanan, Rachel Heafield, Monica Ter-Minassian, David C. Christiani, Matthew H. Kulke, Charles S. Fuchs, Anastassia Daskalova, ZhiRong R Qian, Susanne M. Hooshmand, Lauren K. Brais
Publikováno v:
Endocrine-Related Cancer. 20:187-196
The rarity of neuroendocrine tumors (NET) has contributed to a paucity of large epidemiologic studies of patients with this condition. We characterized presenting symptoms and clinical outcomes in a prospective database of over 900 patients with NET.
Autor:
Anirban Maitra, Georg Feldmann, Volker Fendrich, Farzad Esni, Malte Buchholz, Jens Waldmann, Annette Ramaswamy, Michael Mullendore
Publikováno v:
Endocrine-Related Cancer. 14:865-874
The transcription factor Snail represses E-cadherin and induces epithelial–mesenchymal transition, a process also exploited by invasive cancer cells. Aberrant Hedgehog (Hh) signaling was recently observed in a variety of epithelial cancers and it h